share_log

Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target

Benzinga ·  May 9 08:49

Wedbush analyst Robert Driscoll reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment